Effexor ® — Net Sales
Viatris Effexor ® — Net Sales decreased by 9.0% to $62.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.6%, from $59.30M to $62.00M. Over 4 years (FY 2021 to FY 2025), Effexor ® — Net Sales shows a downward trend with a -5.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests sustained brand loyalty or successful lifecycle management, while a decrease indicates potential market share erosion due to generic competition or therapeutic substitution.
Detailed definition
This metric represents the total revenue generated from the sale of the Effexor brand, a mature pharmaceutical product w...
Peer comparison
Comparable to revenue metrics for mature, off-patent, or legacy branded pharmaceutical products at other global drug manufacturers.
vtrs_segment_effexor_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $83.50M | $79.50M | $77.20M | $77.50M | $73.70M | $64.20M | $64.20M | $64.60M | $64.80M | $65.50M | $68.00M | $59.40M | $62.70M | $66.30M | $64.50M | $59.30M | $63.10M | $67.20M | $68.10M | $62.00M |
| QoQ Change | — | -4.8% | -2.9% | +0.4% | -4.9% | -12.9% | +0.0% | +0.6% | +0.3% | +1.1% | +3.8% | -12.6% | +5.6% | +5.7% | -2.7% | -8.1% | +6.4% | +6.5% | +1.3% | -9.0% |
| YoY Change | — | — | — | — | -11.7% | -19.2% | -16.8% | -16.6% | -12.1% | +2.0% | +5.9% | -8.0% | -3.2% | +1.2% | -5.1% | -0.2% | +0.6% | +1.4% | +5.6% | +4.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's effexor ® — net sales?
- Viatris (VTRS) reported effexor ® — net sales of $62.00M in Q1 2026.
- How has Viatris's effexor ® — net sales changed year-over-year?
- Viatris's effexor ® — net sales increased by 4.6% year-over-year, from $59.30M to $62.00M.
- What is the long-term trend for Viatris's effexor ® — net sales?
- Over 4 years (2021 to 2025), Viatris's effexor ® — net sales has grown at a -5.0% compound annual growth rate (CAGR), from $316.80M to $257.70M.
- What does effexor ® — net sales mean?
- The total revenue earned from sales of the Effexor pharmaceutical product.